» Articles » PMID: 4977281

Human Immunity to the Meningococcus. II. Development of Natural Immunity

Overview
Journal J Exp Med
Date 1969 Jun 1
PMID 4977281
Citations 240
Authors
Affiliations
Soon will be listed here.
Abstract

Results of the present study suggest that natural immunity to meningococcal disease is initiated, reinforced, and broadened by intermittent carriage of different strains of meningococci throughout life. In young adults, carriage of meningococci in the nasopharynx is an efficient process of immune sensitization. 92% of carriers of serogroup B, C, or Bo meningococci were found to develop increased titers of serum bactericidal activity to their own meningococcal isolate, and 87% developed bactericidal activity to heterologous strains of pathogenic meningococci. The rise in bactericidal titer occurred within 2 wk of onset of the carrier state, and was accompanied by an increase in titer of specific IgG, IgM, and IgA antibodies to meningococci. In early childhood, when few children have antibodies to pathogenic meningococci, active immunization seems to occur as a result of carriage of atypical, nonpathogenic strains. Immunity to systemic meningococcal infection among infants in the neonatal period is associated with the passive transfer of IgG antibodies from mother to fetus. The antigenic determinants which initiate the immune response to meningococci include the group-specific C polysaccharide, cross-reactive antigens, and type-specific antigens.

Citing Articles

Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study.

Shoukat A, Wells C, Shin T, Potter-Schwartz L, Galvani A, Moghadas S Lancet Reg Health Am. 2025; 44:101033.

PMID: 40046840 PMC: 11880592. DOI: 10.1016/j.lana.2025.101033.


Increasing human monoclonal antibody cloning efficiency with a whole-cell modified immunoglobulin-capture assay (mICA).

Siris S, Gladstone C, Guo Y, Patel R, Pinder C, Shattock R Front Immunol. 2023; 14:1184510.

PMID: 37334357 PMC: 10272928. DOI: 10.3389/fimmu.2023.1184510.


Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.

Haidara F, Umesi A, Sow S, Ochoge M, Diallo F, Imam A N Engl J Med. 2023; 388(21):1942-1955.

PMID: 37224196 PMC: 10627475. DOI: 10.1056/NEJMoa2214924.


Genetic, Functional, and Immunogenic Analyses of the -Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.

Naess L, Maugesten I, Caugant D, Kassu A, Aseffa A, Borud B J Bacteriol. 2023; 205(3):e0045822.

PMID: 36852982 PMC: 10029716. DOI: 10.1128/jb.00458-22.


A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.

Biselli R, Nisini R, Lista F, Autore A, Lastilla M, De Lorenzo G Biomedicines. 2022; 10(8).

PMID: 36009598 PMC: 9405556. DOI: 10.3390/biomedicines10082050.


References
1.
Kingsbury D . Deoxyribonucleic acid homologies among species of the genus Neisseria. J Bacteriol. 1967; 94(4):870-4. PMC: 276747. DOI: 10.1128/jb.94.4.870-874.1967. View

2.
Gotschlich E, Liu T, Artenstein M . Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med. 1969; 129(6):1349-65. PMC: 2138651. DOI: 10.1084/jem.129.6.1349. View

3.
Eickhoff T, FINLAND M . CHANGING SUSCEPTIBILITY OF MENINGOCOCCI TO ANTIMICROBIAL AGENTS. N Engl J Med. 1965; 272:395-8. DOI: 10.1056/NEJM196502252720804. View

4.
GROOVER R, Sutherland J, LANDING B . Purulent meningitis of newborn infants. Eleven-year experience in the antibiotic era. N Engl J Med. 1961; 264:1115-21. DOI: 10.1056/NEJM196106012642201. View

5.
Goldschneider I, Gotschlich E, Artenstein M . Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969; 129(6):1307-26. PMC: 2138650. DOI: 10.1084/jem.129.6.1307. View